Log in to save to my catalogue

CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia

CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2467843820

CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia

About this item

Full title

CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia

Publisher

United States: Massachusetts Medical Society

Journal title

The New England journal of medicine, 2021-01, Vol.384 (3), p.252-260

Language

English

Formats

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

Two patients, one with transfusion-dependent β-thalassemia and the other with sickle cell disease, received autologous CD34+ cells edited with CRISPR-Cas9 targeting of
BCL11A
. Their clinical course over the following 16 to 18 months supports further experimental testing of CRISPR-Cas9 gene editing to treat these diseases.

Alternative Titles

Full title

CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2467843820

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2467843820

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa2031054

How to access this item